Indegene targets EBITDA recovery in H2FY27
NiveshIQ
NSE: INDGN · Healthcare
Indegene Ltd.
₹578.35▲ ₹1.00 (+0.17%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on INDGN. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Indegene Ltd.
Indegene Limited is a digital-first life sciences commercialization firm headquartered in Bengaluru, operating across India, the United States, Europe, and North America. Its core business is AI‑embedded commercialization services for biopharmaceuticals, emerging biotech, and medical devices, delivered through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other. In FY27 Q2, the company reported revenue of ₹3,813 crore and net income of ₹401 crore, reflecting steady growth driven by expanding omnichannel activation and analytics offerings. Recent developments include preliminary approval of a $4.72 million U.S. class action settlement and bullish technical signals that suggest a potential uptrend. Indegene’s competitive position is strengthened by its pr
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,590 Cr +309.80% | ₹2,839 Cr +9.60% | ₹3,510 Cr +23.60% |
| EBITDA Margin | 19.54% | 18.84% | 17.96% |
| Net Profit | ₹337.00 Cr +587.80% | ₹408.00 Cr +21.10% | ₹400.70 Cr -1.80% |
| EPS | ₹15.17 | ₹16.98 | ₹16.70 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Indegene outlines AI strategy and multi-billion vision
Indegene Q2 FY27: Date and Expectations
🔒
+ 3 more stories about Indegene Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 063 Cr, PAT ₹116 Cr, EPS ₹4.84, EBITDA margin 19.1%. Growth context: revenue QoQ +5.9%, PAT QoQ +45.8%. Street verdict: inline, revenue surprise +0.6%, PAT surprise +4.6%.
Management highlights product launches, approvals, and therapy‑mix improvement as the primary near‑term growth lever, wi...
FY26 (last completed FY): revenue ₹3, 510 Cr, PAT ₹401 Cr, EBITDA margin 18.0%, EPS ₹16.70. Year-on-year: revenue YoY +2...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for INDGN
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track INDGN alongside your other holdings
Unlock full INDGN research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Indegene Ltd.?
NiveshIQ detects active intelligence signals for Indegene Ltd. (INDGN) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Indegene Ltd.?
Indegene Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,273,680.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.